Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Ambroxol Chaperone Therapy for Gaucher Disease Type I-Associated Liver Cirrhosis and Portal Hypertension: A Case Report

Author(s): Peng Zhang, Mei-Fang Zheng, Shi-Yuan Cui, Wei Zhang and Run-Ping Gao*

Volume 22, Issue 6, 2022

Published on: 03 February, 2022

Page: [658 - 662] Pages: 5

DOI: 10.2174/1871530321666211119145230

Price: $65

Abstract

Background: Gaucher Disease (GD) is a rare autosomal recessive inherited disease caused by the deficiency of glucocerebrosidase and characterized by a broad spectrum of clinical manifestations, including hepatosplenomegaly, bone infiltration, and cytopenia. Moreover, it is even involved in the central nervous system. GD is classified into three phenotypes on the ground of neurologic involvement: type 1 (GD1), the commonly adult-onset, non-neuropathic variant; type 2 (GD2), the acute neuropathic form; and type 3 (GD3), the severe chronic neuro-visceral form. Recently, several studies have shown a promising outcome of ambroxol chaperone therapy for the treatment of GD, but its therapeutic role in GD1-associated liver cirrhosis and portal hypertension was not verified.

Case Presentation: A 36-year-old male patient was admitted for esophageal varices lasting for one year with a 34-year history of liver and spleen enlargement. The patient was diagnosed with GD1 with cirrhosis and portal hypertension based on the identification of Gaucher cells and advanced fibrosis in the liver biopsy tissue and two known pathogenic mutations on the glucocerebrosidase (GBA) gene. The patient received 660 mg/d of ambroxol for up to two years. At his six-month follow- up, the patient exhibited a remarkable increase in GBA activity (+35.5%) and decrease in liver stiffness (-19.5%) and portal vein diameter (-41.2%) as examined by ultrasound elastography and computer tomography, respectively. At two-year follow-up, the liver stiffness was further reduced (-55.5%) in comparison with untreated patients.

Conclusion: This case report suggests that long-term treatment with high dose ambroxol may play a role in the reduction of hepatic fibrosis in GD1.

Keywords: Gaucher disease, gaucher cell, liver cirrhosis, portal hypertension, ambroxol, glucocerebrosidase.

« Previous
[1]
Carubbi, F.; Cappellini, M.D.; Fargion, S.; Fracanzani, A.L.; Nascimbeni, F. Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist. Dig. Liver Dis., 2020, 52(4), 368-373.
[http://dx.doi.org/10.1016/j.dld.2020.01.004] [PMID: 32057684]
[2]
Mehta, A. Epidemiology and natural history of Gaucher’s disease. Eur. J. Intern. Med., 2006, 17(Suppl.), S2-S5.
[http://dx.doi.org/10.1016/j.ejim.2006.07.005] [PMID: 17011471]
[3]
Liao, H.C.; Chiang, C.C.; Niu, D.M.; Wang, C.H.; Kao, S.M.; Tsai, F.J.; Huang, Y.H.; Liu, H.C.; Huang, C.K.; Gao, H.J.; Yang, C.F.; Chan, M.J.; Lin, W.D.; Chen, Y.J. Detecting multiple lysosomal storage diseases by tandem mass spectrometry-a national newborn screening program in Taiwan. Clin. Chim. Acta, 2014, 431, 80-86.
[http://dx.doi.org/10.1016/j.cca.2014.01.030] [PMID: 24513544]
[4]
Kang, L.; Zhan, X.; Gu, X.; Zhang, H. Successful newborn screening for Gaucher disease using fluorometric assay in China. J. Hum. Genet., 2017, 62(8), 763-768.
[http://dx.doi.org/10.1038/jhg.2017.36] [PMID: 28356566]
[5]
Mistry, P.K.; Cappellini, M.D.; Lukina, E.; Ozsan, H.; Mach Pascual, S.; Rosenbaum, H.; Helena Solano, M.; Spigelman, Z.; Villarrubia, J.; Watman, N.P.; Massenkeil, G. A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am. J. Hematol., 2011, 86(1), 110-115.
[http://dx.doi.org/10.1002/ajh.21888] [PMID: 21080341]
[6]
Motta, I.; Filocamo, M.; Poggiali, E.; Stroppiano, M.; Dragani, A.; Consonni, D.; Barcellini, W.; Gaidano, G.; Facchini, L.; Specchia, G.; Cappellini, M.D. A multicentre observational study for early diagnosis of Gaucher disease in patients with Splenomegaly and/or Thrombocytopenia. Eur. J. Haematol., 2016, 96(4), 352-359.
[http://dx.doi.org/10.1111/ejh.12596] [PMID: 26033455]
[7]
Nascimbeni, F.; Cassinerio, E.; Dalla Salda, A.; Motta, I.; Bursi, S.; Donatiello, S.; Spina, V.; Cappellini, M.D.; Carubbi, F. Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease. Mol. Genet. Metab., 2018, 125(1-2), 64-72.
[http://dx.doi.org/10.1016/j.ymgme.2018.08.004] [PMID: 30115580]
[8]
Cazan, D.; Klimek, L.; Sperl, A.; Plomer, M.; Kölsch, S.; Kölsch, S. Safety of ambroxol in the treatment of airway diseases in adult patients. Expert Opin. Drug Saf., 2018, 17(12), 1211-1224.
[http://dx.doi.org/10.1080/14740338.2018.1533954] [PMID: 30372367]
[9]
Zimran, A.; Altarescu, G.; Elstein, D. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. Blood Cells Mol. Dis., 2013, 50(2), 134-137.
[http://dx.doi.org/10.1016/j.bcmd.2012.09.006] [PMID: 23085429]
[10]
Pawlinski, L.; Krawczyk, M.; Fiema, M.; Tobor, E.; Kiec-Wilk, B. Dual-action ambroxol in treatment of chronic pain in Gaucher Disease. Eur. J. Pain, 2020, 24(5), 992-996.
[http://dx.doi.org/10.1002/ejp.1538] [PMID: 31994807]
[11]
Han, T.U.; Sam, R.; Sidransky, E. Small molecule chaperones for the treatment of gaucher disease and GBA1-associated parkinson disease. Front. Cell Dev. Biol., 2020, 8, 271.
[http://dx.doi.org/10.3389/fcell.2020.00271] [PMID: 32509770]
[12]
Oulaïdi, F.; Front-Deschamps, S.; Gallienne, E.; Lesellier, E.; Ikeda, K.; Asano, N.; Compain, P.; Martin, O.R. Second-generation iminoxylitol-based pharmacological chaperones for the treatment of Gaucher disease. ChemMedChem, 2011, 6(2), 353-361.
[http://dx.doi.org/10.1002/cmdc.201000469] [PMID: 21275057]
[13]
Maegawa, G.H.; Tropak, M.B.; Buttner, J.D.; Rigat, B.A.; Fuller, M.; Pandit, D.; Tang, L.; Kornhaber, G.J.; Hamuro, Y.; Clarke, J.T.; Mahuran, D.J. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J. Biol. Chem., 2009, 284(35), 23502-23516.
[http://dx.doi.org/10.1074/jbc.M109.012393] [PMID: 19578116]
[14]
Luan, Z.; Li, L.; Higaki, K.; Nanba, E.; Suzuki, Y.; Ohno, K. The chaperone activity and toxicity of ambroxol on Gaucher cells and normal mice. Brain Dev., 2013, 35(4), 317-322.
[http://dx.doi.org/10.1016/j.braindev.2012.05.008] [PMID: 22682976]
[15]
Narita, A.; Shirai, K.; Itamura, S.; Matsuda, A.; Ishihara, A.; Matsushita, K.; Fukuda, C.; Kubota, N.; Takayama, R.; Shigematsu, H.; Hayashi, A.; Kumada, T.; Yuge, K.; Watanabe, Y.; Kosugi, S.; Nishida, H.; Kimura, Y.; Endo, Y.; Higaki, K.; Nanba, E.; Nishimura, Y.; Tamasaki, A.; Togawa, M.; Saito, Y.; Maegaki, Y.; Ohno, K.; Suzuki, Y. Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study. Ann. Clin. Transl. Neurol., 2016, 3(3), 200-215.
[http://dx.doi.org/10.1002/acn3.292] [PMID: 27042680]
[16]
Mistry, P.K.; Sadan, S.; Yang, R.; Yee, J.; Yang, M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am. J. Hematol., 2007, 82(8), 697-701.
[http://dx.doi.org/10.1002/ajh.20908] [PMID: 17492645]
[17]
Mehta, A.; Belmatoug, N.; Bembi, B.; Deegan, P.; Elstein, D.; Göker-Alpan, Ö.; Lukina, E.; Mengel, E.; Nakamura, K.; Pastores, G.M.; Pérez-López, J.; Schwartz, I.; Serratrice, C.; Szer, J.; Zimran, A.; Di Rocco, M.; Panahloo, Z.; Kuter, D.J.; Hughes, D. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Mol. Genet. Metab., 2017, 122(3), 122-129.
[http://dx.doi.org/10.1016/j.ymgme.2017.08.002] [PMID: 28847676]
[18]
Mistry, P.K.; Lopez, G.; Schiffmann, R.; Barton, N.W.; Weinreb, N.J.; Sidransky, E. Gaucher disease: Progress and ongoing challenges. Mol. Genet. Metab., 2017, 120(1-2), 8-21.
[http://dx.doi.org/10.1016/j.ymgme.2016.11.006] [PMID: 27916601]
[19]
Bohte, A.E.; van Dussen, L.; Akkerman, E.M.; Nederveen, A.J.; Sinkus, R.; Jansen, P.L.; Stoker, J.; Hollak, C.E. Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage. PLoS One, 2013, 8(3), e57507.
[http://dx.doi.org/10.1371/journal.pone.0057507] [PMID: 23554863]
[20]
Webb, M.; Zimran, A.; Dinur, T.; Shibolet, O.; Levit, S.; Steinberg, D.M.; Salomon, O. Are transient and shear wave elastography useful tools in Gaucher disease? Blood Cells Mol. Dis., 2018, 68, 143-147.
[http://dx.doi.org/10.1016/j.bcmd.2016.12.010] [PMID: 28063644]
[21]
Belkouch, M.; Dansereau, M.A.; Tétreault, P.; Biet, M.; Beaudet, N.; Dumaine, R.; Chraibi, A.; Mélik-Parsadaniantz, S.; Sarret, P. Functional up-regulation of Nav1.8 sodium channel in Aβ afferent fibers subjected to chronic peripheral inflammation. J. Neuroinflammation, 2014, 11, 45.
[http://dx.doi.org/10.1186/1742-2094-11-45] [PMID: 24606981]
[22]
Löken, L.S.; Duff, E.P.; Tracey, I. Low-threshold mechanoreceptors play a frequency-dependent dual role in subjective ratings of mechanical allodynia. J. Neurophysiol., 2017, 118(6), 3360-3369.
[http://dx.doi.org/10.1152/jn.00977.2016] [PMID: 28954896]

Rights & Permissions Print Cite
Article Metrics
34
1
© 2024 Bentham Science Publishers | Privacy Policy